A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

NCT00514371 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: tanespimycin
DRUG: Bortezomib

Sponsor

Bristol-Myers Squibb